share_log

RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $82

RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $82

RBC資本維持對Cytokinetics的跑贏大市評級,將目標價格提高至82美元
Benzinga ·  12/18 09:43  · 評級/大行評級

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $80 to $82.

RBC Capital 分析師Leonid Timashev維持對Cytokinetics(納斯達克:CYTK)的評級爲跑贏大盤,並將目標價格從80美元提高到82美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論